Biotechnology

Biotech’s ‘Builder’ Phase: AI Integration Drives R&D Transformation The biotech industry is shifting from standalone artificial intelligence tools to developing fully integrated, AI-native discovery systems. According to the 2026 Biotech AI Report from Benchling, this new “builder” phase sees organizations reshaping their data infrastructure and company structures to make AI a core component of their research and development models. A common trend is to embed AI leadership directly within R&D to ensure technology remains connected to the experimental context. However, the report highlights that poor data quality and availability are the top reasons for the failure of AI pilot projects. These infrastructure issues are creating a significant bottleneck for AI adoption in more complex areas like generative design and biomarker analysis. ...

MIT Unveils BoltzGen: A Generative AI for Designing Therapeutic Molecules In a major leap for drug discovery, scientists at MIT have introduced BoltzGen, a generative AI model capable of creating novel protein binders from scratch. This innovative tool is designed to address diseases that have long been considered difficult or impossible to treat, marking a significant shift from predictive biology to generative engineering in medicine. How BoltzGen Unifies Design and Prediction BoltzGen stands out by unifying protein design and structure prediction into a single, powerful process. The model incorporates specific constraints to ensure that the molecules it generates are not only novel but also functional and stable, adhering to the fundamental laws of physics and chemistry. Unlike previous models that were often limited to specific protein types, BoltzGen is engineered as a more general-purpose tool, capable of creating a much wider range of therapeutic molecules. ...

MIT Unveils TX-GAIN, The Most Powerful University AI Supercomputer MIT’s Lincoln Laboratory has launched the TX-Generative AI Next (TX-GAIN) computing system, now the most powerful AI supercomputer at any U.S. university. Optimized for generative AI, TX-GAIN is set to drive innovation in critical research areas such as biodefense, materials discovery, and cybersecurity. With a peak performance of two AI exaflops, the supercomputer will support a wide range of research and development projects at Lincoln Laboratory and across the MIT campus. Researchers are already utilizing TX-GAIN to model complex protein interactions for biological defense, demonstrating its significant impact on scientific breakthroughs. The system is housed in an energy-efficient data center in Holyoke, Massachusetts. ...